2021
COVID-19's natural course among ambulatory monitored outpatients
WEINBERGEROVÁ, Barbora, Jiří MAYER, Štěpán HRABOVSKÝ, Zuzana NOVÁKOVÁ, Zdeněk POSPÍŠIL et. al.Základní údaje
Originální název
COVID-19's natural course among ambulatory monitored outpatients
Autoři
WEINBERGEROVÁ, Barbora (203 Česká republika, garant, domácí), Jiří MAYER (203 Česká republika, domácí), Štěpán HRABOVSKÝ (203 Česká republika, domácí), Zuzana NOVÁKOVÁ (203 Česká republika, domácí), Zdeněk POSPÍŠIL (203 Česká republika, domácí), Lucie MARTYKÁNOVÁ (203 Česká republika, domácí), Katerina HORTOVA (203 Česká republika), Lucie MANDELOVA (203 Česká republika), Karel HEJDUK (203 Česká republika, domácí), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Michal POSPÍŠIL (203 Česká republika, domácí), Martina DOUBKOVÁ (203 Česká republika, domácí), Vladimír MAREK (203 Česká republika, domácí), Renata NOVOTNA (203 Česká republika), Martin DOLEČEK (203 Česká republika, domácí), Hana MATĚJOVSKÁ KUBEŠOVÁ (203 Česká republika, domácí), Kristián BRAT (703 Slovensko, domácí), Radana PAŘÍZKOVÁ (203 Česká republika, domácí), Petr HUSA (203 Česká republika, domácí), Marek MECHL (203 Česká republika, domácí), Zdeněk KRÁL (203 Česká republika, domácí) a Martina LENGEROVÁ (203 Česká republika, domácí)
Vydání
Nature Scientific Reports, London, NATURE RESEARCH, 2021, 2045-2322
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10700 1.7 Other natural sciences
Stát vydavatele
Německo
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.996
Kód RIV
RIV/00216224:14110/21:00121827
Organizační jednotka
Lékařská fakulta
UT WoS
000652603700004
Klíčová slova anglicky
COVID-19; ambulatory monitored outpatients
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 5. 4. 2022 13:35, Mgr. Tereza Miškechová
Anotace
V originále
Research objective was to detail COVID-19's natural trajectory in relation to the Czech population's viral load. Our prospective detailed daily questionnaire-based telemonitoring study evaluated COVID-19's impact among 105 outpatients. In accordance with government quarantine requirements, outpatients were divided into a cohort with two negative tests at the end of the disease (40 patients) and a cohort with a new algorithm (65 patients) following a 14-day quarantine. Median follow-up differed significantly between the 2 groups (23 days vs. 16 days). Only 6% of patients were asymptomatic during the entire telemonitoring period. Another 13% of patients were diagnosed asymptomatic, as suspected contacts, yet later developed symptoms, while the remaining 81% were diagnosed as symptomatic on average 6 days following symptom onset. Telemonitoring enabled precise symptom status chronicling. The most frequently reported complaints were fevers, respiratory issues, and anosmia. Six patients were eventually hospitalized for complications detected early after routine telemonitoring. During the extended follow-up (median 181 days), anosmia persisted in 26% of patients. 79% of patients in the new quarantine algorithm cohort reported no symptoms on day 11 compared to just 56% of patients in the two negative test cohort upon first testing negative (median-19 days). The highest viral load occurred within 0-2 days of initial symptom onset. Both the PCR viral load and two consecutive PCR negative sample realizations indicated high interindividual variability with a surprisingly fluctuating pattern among 43% of patients. No definitive COVID-19 symptoms or set of symptoms excepting anosmia (59%) and/or ageusia (47%) were identified. No preexisting medical conditions specifically foreshadowed disease trajectory in a given patient. Without a PCR negativity requirement for quarantine cessation, patients could exhibit fewer symptoms. Our study therefore highlights the urgent need for routine ambulatory patient telemedicine monitoring, early complication detection, intensive mass education connecting disease demeanor with subsequent swift diagnostics, and, notably, the need to reevaluate and modify quarantine regulations for better control of SARS-CoV-2 proliferation.